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Abstract
Background: Disease modifying treatments (DMT) for MS such as interferon beta (IFNβ) have been shown to
reduce the risk for disease progression. Therefore adherence to treatment is essential for treatment outcome.Here
we want to evaluate if participation in a patient management program (PMP) improves adherence to DMT as well
as health and cost outcomes associated with MS.
Methods: In this open-label multicentre prospective observational study, German MS patients treated with once
weekly intramuscular (IM) IFNβ-1a (Avonex ®), were offered participation in a PMP and followed for up to
12 months. The PMP included injection trainings, support and quarterly visits for up to 12 months after initiation of
therapy. Utilisation of health care services was evaluated.
The primary endpoint was to evaluate the direct and indirect cost associated with MS from payer, patient and
societal perspective, in patients who participate in the PMP. Secondary endpoint was the clinical outcome in
patients who participate in the PMP (differentiated in adherent versus non-adherent patients).
Results: In total 731 patients (mean age: 38.2, 73.7 % female) were enrolled, 640 (88 %) were observed for twelve
months. After six months 34 % of patients had participated in the PMP continuously and 21 % temporarily; 39 %
had not participated. After twelve months, the proportions of participants were: 37 % continuously and 19 %
temporarily; 40 % had not participated.
After 6 months, mean reduction in cost per patient in the participants group (€ 2151) was almost twice as high as
the cost reduction amongst non-participants (€ 1131).
After twelve months, the annual relapse rate was reduced by 58 % compared to baseline in both the participant
and non-participant groups.
Conclusions: In a real-world-setting, participation in a patient management program was associated with improved
medication adherence and lower total MS-related direct and indirect cost over time.
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Background
Multiple sclerosis (MS) is an inflammatory and progres-
sive disease of the central nervous system with a hetero-
geneous clinical course. MS usually begins with an acute
inflammatory demyelinating episode (clinically isolated
syndrome, CIS) turning to relapsing-remitting MS (RRMS)
characterized by discrete acute attacks of worsening neuro-
logical function (relapses) that are followed by partial or
complete recovery (remission). Residual disability may ac-
cumulate over time and many patients with RRMS develop
secondary progressive MS, which is characterized by pro-
gressive neurological decline [1].
Therapeutic options in MS include treatment of acute
relapses, immunomodulating disease-modifying drugs
(DMD), and symptomatic therapy. A large number of
randomized clinical trials showed that DMDs reduce
relapse rates, decrease the occurrence of new lesions on
magnetic resonance imaging (MRI), and reduce dis-
ease progression in patients with MS [2–7]. Apart
from recently introduced oral drugs, first-line DMDs
are self-administered parenterally (subcutaneously or
intramuscularly) on a regular basis by the patient and are
given daily to once weekly, depending on the product.
Although treatment efficacy has been established, adher-
ence and persistence to pharmacotherapy in the long-term
remains one of the main challenges and is a key factor in
predicting long-term outcomes. Continuous use of DMTs
provides the greatest benefit by preventing relapses and
delaying disease progression [8, 9]. Furthermore, DMT-
adherent patients experience higher quality of life [10, 11],
show reduced absenteeism [9], require less health-care re-
sources and cause lower medical cost [9, 12]. Published ad-
herence rates in RRMS patients are 41–88 % depending on
study and definition of adherence [10, 11, 13, 14]. Several
studies comparing adherence rates for routine therapy
using different DMTs reported the highest values for once-
weekly interferon beta-1a (IM IFNb-1a) (79–85 vs. 49–
78 % for other DMTs) [10, 11]. The risk of discontinuation
of therapy has been shown to be highest early after treat-
ment initiation, i.e., within the first 6 months to 2 years [15,
16]. Optimal adherence to immunotherapy is essential for
MS patients to achieve the full long-term benefit of their
therapies. However, patients with MS face several barriers
to optimal treatment adherence. Multiple therapy-related
factors such as adverse events (e.g., flu-like symptoms,
injection-site reactions), efficacy concerns or injection-
related reasons can result in non-adherence. Additionally,
adherence may be affected by the patients’ cognitive im-
pairment, depression, inadequate expectations, knowledge
deficits or the patient´s attitude towards himself and the
disease. Other factors such as social/family support, rela-
tionship between patient and healthcare provider, and
socio-economic factors were also identified as factors that
compromize adherence [10, 11, 17, 18].
Optimizing adherence to MS therapy is an important
therapeutic goal. The substantial economic burden asso-
ciated with MS results from direct medical cost associ-
ated with healthcare and disability-related resource
utilization as well as indirect cost related to reduced
productivity [19]. Non-adherence has been shown to be
associated with higher MS-related medical cost [12].
Therefore improving poor adherence could result in
benefits for patients, payers and society. Strategies to en-
hance adherence to DMTs include managing patient ex-
pectations and adverse events, educating patient and
family and importantly establishing a good relationship
between patients and treating physicians [17]. Adher-
ence to therapy can also be improved by providing the
patient with a supporting network. Specialized MS
nurses can give valuable assistance advising the patient
on the management of symptoms, side-effects or injec-
tion anxiety. Many studies have reported the potential
benefit of patient management programs (PMPs) in
other therapeutic areas such as diabetes, coronary ar-
tery disease or asthma [20].
The context of PMPs enables continuous patient edu-
cation and consistent confirmation of treatment benefit
[21]. A structured PMP with specialized nurses or skilled
healthcare workers supporting the patients after starting
immunotherapy may have a substantial impact on MS
patient outcomes. Therefore, the patient management
program MS-CARE has been introduced in Germany. It
offers personalized injection training, regular telephone-
based or personal counselling, patient education services,
and exchange of experiences.
The aim of the present study C.A.R.E.. (Does personal
Care for Avonex® patients with RRMS increase Effective-
ness of treatment?) was to investigate the impact of a
PMP on patients’ adherence, and clinical and economical
outcomes among patients with MS treated with once
weekly IM IFNb-1a.
Methods
C.A.R.E. was an open-label non-interventional, obser-
vational, prospective, multicenter study conducted in
Germany between February 2009 and December 2010,
investigating the impact of a structured PMP on pa-
tients’ treatment adherence and associated health and
economical outcomes. The patients were observed for
12 months in a real-world clinical practice setting. Adult
patients with a clinically isolated syndrome (CIS), or with
a diagnosis of RRMS who had received a prescription for
once weekly IM IFNb-1a for at least one month before in-
clusion were included in the non-interventional study.
The study was conducted in agreement with the Inter-
national Conference on Harmonisation (ICH) and Good
Clinical Practice (GCP) guidelines and followed Declaration
of Helsinki recommendations. Prof. Dr. Karl H. Jakobs,
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representative for the ethics commission of the Medical
Faculty of the University Duisburg-Essen (Ethik-Kommis-
sion, Robert-Koch-Str. 9–11, 45147 Essen, Germany), ap-
proved the study. All patients provided written informed
consent.
Data collection
Data collection was based on physician and patient ques-
tionnaires (administered to physicians every 3 months,
and to patients every 6 months). At study initiation
(visit 1) physicians collected the patients’ demographic
data, medical history, date of MS diagnosis, prior treat-
ment with other DMTs, current disease characteristics,
and the type of pharmaceutical formulation used for
IM IFNb-1a therapy. The patients also reported if they
self-injected IM IFNb-1a or required assistance. At the
following quarterly visits, physicians documented the IM
IFNb-1a treatment status and the course of disease (re-
lapses, affected functional systems, steroid therapy, and
hospitalizations). The patients’ adherence was rated on a
10-step scale (1 = excellent, 10 = very poor) as judged by
the physician. Patients with ratings of 2 or lower were
considered adherent since adherence of at least 80 % is a
widely accepted adherence criterion [22, 23].
At study initiation and after 6 and 12 months, respect-
ively, the patients completed a patient survey. This ques-
tionnaire included questions concerning professional life,
general practitioner and specialist visits, examinations,
hospital care (inpatient, outpatient), rehabilitation, home
care, expenses for medication (non-prescription drugs, an-
algesics, nutritional supplements), investments, and acqui-
sitions of aids and appliances. The patient questionnaires
also provided information about participation in the PMP.
At visit 1, the patients were offered participation in
the PMP MS-CARE. Patients who participated in the
PMP are denoted “participants” and those who did not,
“non-participants”. The PMP was based on individual
patient education by MS nurses. They provided consist-
ent education on MS as disease, treatment, and motiv-
ation for treatment. The nurses performed injection
trainings within the first weeks of therapy and provided
advice on improving injection technique and tolerabil-
ity. Following this initial training, the same nurse sup-
ported the individual patient, provided motivation, and
monitored adherence throughout the study. During
regular personal meetings or by telephone, the nurses
provided general advice and helped improve injection
handling. Information and service material was pro-
vided upon request.
In the economic analyses, cost was evaluated from the
payer (statutory health insurance (SHI), statutory pen-
sion insurance), patient, and societal perspectives. Direct
cost from payer perspective include cost for physician
visits and medical services in the outpatient setting,
hospitalisations, inpatient and outpatient rehabilitation
measures, and nursing home. Cost for IM IFNb-1a was
not considered in the analysis. Direct cost from patient
perspective included co-payments (e.g., for wheelchair,
medical devices, glasses), expenses for non-prescription
medication and transportation, and modifications of
home and car (e.g., elevator). Indirect cost from societal
perspective included productivity losses due to workdays
lost. For the calculation of indirect cost, the number of
days absent from work was multiplied with the average
loss of productivity per day. The economic evaluation
was done in accordance with German recommendations
for health economic evaluations [24].
Unit cost of physician visits and medical services at
office-based practices was derived from the official
German physicians` fee schedule (“Einheitlicher
Bewertungsmaßstab”, EBM, 2011) [25]. Unit cost for
visits to other specialists (ergotherapy, physiotherapy,
alternative medicine) was taken from the AOK (a statutory
health insurance company) homepage [26] and the alter-
native practitioners homepage [27]. Unit cost for hospitali-
sations due to MS was based on case related allowances
using German diagnosis related groups (G-DRG) [28, 29];
an average base rate of € 2964 was used for calculation.
Since official nationwide unit cost for outpatient rehabili-
tation and inpatient rehabilitation was not available,
unit cost per day was taken from homepages of indi-
vidual rehabilitation hospitals. Based on gross income
data and the number of persons in paid employment,
the monetary value of productivity loss per day
(€133.85) for employed persons was calculated [30].
Cost from the patient perspective was directly derived
from patients’ questionnaires.
Statistical analysis
Continuous data were analysed by descriptive statistics
(number, mean, standard deviation, minimum, 5th, 25th,
75th, and 95th percentile, maximum; for cost data per-
centiles are not shown). Percentages given in the Table 1
are based on the proportions of patients with available
data for the respective item. For categorical parameters,
absolute and relative frequencies were calculated. Rela-
tive frequencies refer to the number of patients with
evaluable data. The number of patients with evaluable
data may vary between different analyses.
Results
Data from 731 patients with CIS or RRMS on once
weekly IM IFNb-1a were included in the analysis. Demo-
graphic data and baseline disease characteristics of the
total study population are shown in Table 1.
Among the included patients, 73.7 % were female, the
mean age at baseline was 38.2 ± 10.8 years. Patient med-
ical history revealed that the patients had on average 1.3
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relapses (range 0–6) in the year before inclusion in the
study. Mean duration of MS prior to baseline visit was
5.2 years (range 1–41 years).
The mean adherence rating was “good”, i.e., 2.0 (±1,9)
on an ordinal scale from 1 (“excellent”) to 10 (“very
poor”) as judged the treating neurologist.
For several subgroup analyses, e.g., impact of the PMP
on adherence, effectiveness or cost, data from the patient
questionnaires were used. An overview of the numbers
of patients with evaluable data from the questionnaires
at different time points is given in Fig. 1. In total, the pa-
tient questionnaire was completed by 88 % (640/731) of
patients. At visits 1 (baseline), 3 (at 6 months), and 5 (at
12 months), respectively, 99 % (634/640), 76 % (487/
640), and 79 % (503/640) of patients completed the
questionnaire. Because of the non-interventional charac-
ter of the study, PMP participation was voluntary. At
visit 3 (6 months) 54 % (261/487) of patients who had
completed the questionnaire indicated that they had par-
ticipated in the PMP while 191 patients (39 %) did not
participate (data missing for 35 patients). At 12 months,
38 % (190/503) patients had further participated in the
PMP whereas 137 patients (27 %) did not participate
(data were missing for 176 patients).
Data for cost evaluation at visit 1 were available for
68 % of patients (433/640), at both visit 1 and visit 3 for
61 % (393/640), and data from all three visits (12 months
period) were available for 39 % (251/640).
The proportion of patients with available data for cost
analysis at visits 1 and 3 (six months period) who had par-
ticipated in the PMP was 55 % (216/393); 40 % (154/393)
were non-participants (data were missing for 23 patients).
The mean age of documented PMP participants was
38.2 years at visit 3 and 38.1 years at visit 5 (12 months)
(Table 2). Participants were slightly younger than non-
participants (mean age 38.2 vs. 39.2 years, and 38.1 vs.
40.0 years at 6 and 12 months, respectively). The propor-
tion of women was slightly higher in the PMP participant
group (76.2 % at 6 months and 77.9 % at 12 months) ver-
sus non-participants (70.5 % and 75.7 %). There was no
significant difference in mean annual relapse rate and pro-
portion of prior MS therapies between participants and
non-participants.
Fig. 1 Study overview: flow chart representing the patient flow through consecutive study visits
Table 1 Demographic data and baseline characteristics of the
study population (all patients, documentation in physician
questionnaires)
Patient population
Patients enrolled [n] 731
Therapy discontinuation: No [n] 614 [84 %]
Yes [n] 117 [16 %]




Age [years], mean/median (range) 38.2 (+/−10,8)/ 39 (17–69)
Gender, female [%] 73.7
# Relapses 12 months prior to baseline
[n], mean/median (range)
1.3/1.0 (0–6)
Duration of MS before baseline [years],
mean/median (range)
5.2/2.0 (1–41)
Prior MS therapies [%]
No 485 [66.4 %]
Yes 245 [33.6 %]
Missing 1
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Adherence
Overall treatment with once weekly IM IFNb-1a was as-
sociated with high physician-reported adherence during
the 12 months observational period. The mean adher-
ence rating over all patients was 1.9 (“good”) at visit 2
after 3 months and 2.0 (“good”) at all following visits
(data not shown). After 12 months, 96.3 % of patients
with available data (395/410) were still adherent to once
weekly IM IFNb-1a therapy. The formulation (pre-filled
syringe or lyophilised) of IM IFNb-1a did not have any
impact on adherence (data not shown). Participating in
the PMP showed a trend towards higher adherence rat-
ing by the treating physician (Fig. 2). Participants were
more often rated as adherent (a rating of 2 corresponds
to 80 % adherence) by the treating physician than non-
participants. However, the difference was not statistically
significant (84.2 % vs. 79.6 %; p = 0.3058).
Course of disease
The mean annual relapse rate (ARR) of the total patient
population decreased from 1.3 during the year preced-
ing study entry to 0.4 during the 12 months of study. A
total of 71 % of the patients remained free of relapses
during the study (data not shown). There was no signifi-
cant difference in the mean ARR after 12 months between
PMP participants and non-participants (p = 0.8976). Both
participants and non-participants experienced a mean
of 0.5 relapses within 12 months which corresponds to
a 58 % relative reduction of relapse rates in both
groups (Table 3).
MS-related cost
Data for the economic analysis were derived from the pa-
tients’ questionnaires. At baseline, data for cost evaluation
were available from 433 patients. Only patients with docu-
mentation at least in visits 1 (baseline) and 3 (after
6 months; n = 393) were included in the analysis. After
12 months, this sub-population included 251 patients.
Complete data for cost analysis from societal perspective
for all three visits were available for 167 patients. The total
cost from societal perspective for the six months period
prior to study enrolment was € 2511 ± 3292 per patient.
The cost from the payers’ perspective accounted for 61 %,
from the patients’ perspective for 2 % and the cost for loss
of productivity accounted for 37 % of the total cost.
Within 6 months after study inclusion, the total cost from
Table 2 Demographic data and baseline characteristics of PMP
participants and non-participants (n = 452 at visit 3 (6 months)
and n = 327 at visit 5 (12 months), patient questionnaires)
Participation in PMP
Months 0-6 Months 7-12
Yes No Yes No
Patients [n] 261 191 190 137
Age, mean/median [years] 38.2/38.0 39.2/40.0 38.1/37.5 40.0/41.0
Gender, female [%] 76.2 70.5 77.9 75.7
Number of relapses during
12 months prior to baseline
[n]
1.2 (0.8) 1.2 (1.0) 1.2 (0.8) 1.2 (0.9)
Prior MS therapy [%] No 32.6 31.1 34.7 29.4
























Fig. 2 Neurologists´ rating of patients’ adherence (mean adherence rating) on a 10-step adherence scale (1 = excellent; 10 = very poor);
PMP participants versus non-participants
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societal perspective was reduced to € 951 ± 1967 per
patient (Table 4, Fig. 3). The difference is statistically sig-
nificant (p < 0.0001). This reduction was mainly due to
markedly lower cost for hospital stays (€ 967 to € 56) and
to a lesser extent to reduction in cost for visits to other
specialised health care professionals (€ 69 to € 31), exami-
nations (€ 207 to € 68) and stays at a day-care clinic (€ 76
to € 11). Cost from the payers’ perspective dropped to one
third of baseline cost, indirect cost was reduced to less
than half after 6 months whereas cost from the patients’
perspective remained unchanged. The reduction in total
cost persisted at twelve months (€ 1,009 ± 2,780).
Relationship between PMP participation and cost
To evaluate the impact of PMP participation on MS re-
lated cost data at visit 1 and 3 were analysed from the
societal perspective (n = 281) and from the payers’ per-
spective. (n = 345). After 6 months, the mean cost reduc-
tion per patient from the societal perspective was almost
twice as high in participants (€ 2,151) versus non-
participants (€ 1,131) (Fig. 4a). These reductions are
mostly due to a reduction in cost from the payers’ per-
spective and to a lesser extent to reduced loss of prod-
uctivity. From the payers’ perspective alone (Fig. 4b),
cost as reduced by € 1,322 in the participants group and
by € 731 among non-participants. These savings resulted
mainly from fewer hospital stays, examinations, and
physician visits. Data indicated that reduction in both total
cost and insurance-covered cost (payers’ perspective) was
greatest in patients participating in the PMP. However, for
participants MS-related cost at baseline had been higher
than for non-participants (data not shown).
Relationship between treatment adherence and cost
The cost reduction after start of the study as compared
to the six-month period before is shown for adherent
and non-adherent patients, respectively (Fig. 5). Data of
166 patients at baseline and at 6 and 12 months were
available for analyzing cost stratified for adherence. Of
this subpopulation of patients, 83 % were adherent and
17 % non-adherent. Total cost from the societal per-
spective in the 6 months prior to study start had been
€2,748 ± 3,451 per patient for the adherent patients and
€ 1269 ± 2030 for non-adherent patients. These cost
was reduced to € 951 ± 1,934 and € 845 ± 2,109, re-
spectively, within 6 months. Thus, the cost reduction
was somewhat more pronounced in the adherent group
than in the non-adherent group. However, in the 6 months
before study entry the cost had been higher in the adher-
ent subgroup.
At visit 3 after 6 months, cost was comparable be-
tween adherent and non-adherent patients. The reduc-
tion of mean total cost per patient was maintained for
12 months for both adherent (reduced by € 1,619) and
non-adherent patients (reduced by € 700).
Discussion
This study aimed to provide data on the impact of a
treatment-accompanying PMP on patients’ adherence






During12 months before baseline 1.2 1.2
From baseline to month 12 of study 0.5 0.5
Relative reduction of relapse rate 58 % 58 %
Table 4 Total cost per patient [€] from the societal perspective 6 months before visit 1, visit 3 (month 6) and visit 5 (month 12); patients
with data at baseline, 6 months and 12 months of study (n = 167, cost data without missing data for all three visits), p < 0.0001
Baseline visit Visit at month 6 Visit at month 12
Mean SD Median Min Max Mean SD Median Min Max Mean SD Median Min Max
Direct cost, payer perspective 1,540 2,124 362 0 11,145 506 1,275 120 0 7,071 350 971 121 0 7,770
Visits, other specialists 69 69 0 0 290 31 46 0 0 222 37 56 0 0 273
Physician visits 66 183 0 0 1,369 51 140 0 0 869 70 172 0 0 1,201
Examinations 207 199 186 0 1,512 68 100 0 0 623 72 95 6 0 486
Hospital stays 967 1,632 0 0 6,212 56 414 0 0 3,106 56 414 0 0 3,106
Daycare clinic 76 323 0 0 3,252 11 69 0 0 542 11 69 0 0 542
Inpatient rehabilitation 149 822 0 0 5,893 289 1,173 0 0 7,071 99 759 0 0 7,071
Outpatient rehabilitation 6 44 0 0 416 0 0 0 0 0 6 54 0 0 555
Nursing home stay 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Direct cost, patient perspective 40 98 0 0 730 35 78 0 0 585 37 89 0 0 700
Indirect cost (loss of productivity) 931 2,125 0 0 20,078 410 1,288 0 0 12,047 621 2,421 0 0 24,628
Total cost 2,511 3,292 825 0 22,013 951 1,967 179 0 12,296 1,009 2,780 251 0 24,970








Fig. 3 Mean total cost per 6 months per patient from societal perspective [€] 6 months before visit 1, and at visits 3 (month 6) and 5 (month 12);



























































Fig. 4 Mean reduction in cost per patient after 6 months on study versus 6 months before baseline; PMP participants vs. non-participants. a Mean
reduction in total cost per patient from societal perspective (281 patients with cost data available for visits 1 and 3). b Mean reduction in cost
per patient from payers’ perspective (345 patients with cost data available for visits 1 and 3)
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and associated clinical and economical outcomes among
patients with MS treated with IM IFNb-1a in a real-life
practice setting using physician-based reports and patient
questionnaires.
The overall adherence rate found in this observational
study was approximately 80 % (corresponding to a mean
adherence rating of 2.0). Patients who participated in the
PMP were more adherent than non-participants to once
weekly IM IFNb-1a treatment after 12 months as rated
by the treating physician (84 vs. 79 %, difference statisti-
cally not significant). This suggests a positive effect of
the patient support in the patient management program.
Data from a previous study show that medication adher-
ence and persistence to MS therapy improved among
participants in a PMP but deteriorated among non-
participants [31]. The observed adherence rate is in the
range of several previous retrospective and prospective
studies showing adherence rates between 41 and 88 %
[10, 11, 14].
However, a comparison of adherence rates between dif-
ferent studies is difficult due to different approaches in
measuring adherence. In this non-interventional study,
adherence was rated by the treating physician using per-
sonal judgement compared to methods based on direct
patient interviews concerning the injection related behav-
iour in a certain time period, prescription patterns or
medication possession ratios [9–11, 18, 32, 33]. Data from
a Spanish study indicate that only a minority of patients
informs the neurologist when they skip injections or
interrupt DMT treatment [13]. The physician’s percep-
tion may therefore differ from the patient’s estimate of
adherence. The findings of the global “MS Choices
Survey” suggested that physicians may underestimate
the levels of adherence among their patients [34]. Inter-
estingly we noted no significant difference in adherence
between patients using the pre-filled syringe or the lyo-
philisate. Possibly adherence may be further improved
by advances in delivery technology such as the use of
autoinjectors. In a phase IIIb-study [35], patients pre-
ferred a pen device for administering once weekly IM
IFNb-1a versus a conventional syringe. At the time
when the present study was conducted the pen device
was not yet available. Our study showed that PMP partici-
pants were more often adherent than non-participants.
These results suggest that the PMP may have a positive
impact on patient adherence and might consequently
bring about a higher treatment benefit.
During the 12-month study period, both participants
and non-participants in the PMP showed a 58 % relative
risk reduction in the ARR. However, due to the lack of
control groups, conclusions about efficacy cannot be reli-
ably derived from the data. Furthermore, the observation
period of 12 months is too short to detect any relevant
long-term effects.
One major objective of the present observational study
was to evaluate the effect of the PMP on economical out-
comes. In the total study population, the mean reduction
of cost in 6 month after versus before the initiation of IM
IFNb-1a treatment was € 1066 from payers’ perspective
and € 1502 from the societal perspective. When stratifying
MS-related cost by participation in PMP, participants
showed a higher decrease of mean total MS-related cost
after 6 months than non-participants (reduction by € 2151
vs. € 1131). Total MS-related cost as well were reduced
more strongly in adherent vs. non-adherent patients
(€ 1,619 vs. € 700, respectively). A retrospective co-
hort analysis by Tan et al. in the US demonstrated that
mean MS-related medical cost decreased by € 197 among
participants and increased by US$ 1536 among non-
participants. Participants utilize fewer medical services
Fig. 5 Mean total cost per patient from the societal perspective accrued in 6-months intervals before and during study (167 patients with cost
data at visits 1, 3 and 5); adherent vs. non-adherent patients
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including hospitalizations, emergency department visits
and unscheduled physician office visits [31].
Non-adherence has been related to higher cost for hospi-
talisations, physician and emergency department visits in
another retrospective study [9]. The reductions in cost ob-
served in our observational study were mainly caused by
lower cost for hospital stays indicating a successful im-
provement of clinical outcomes as the hospitalization rate
serves as indicator for severe MS exacerbations [9]. This
may also explain the observed reduction in total MS-
associated cost in non-adherent patients and non-
participants. Both PMP participants and adherent patients
in our study had caused higher MS-associated cost prior to
study entry. These patients may have more severe MS than
non-participants or non-adherent patients and required
more hospital stays. Higher baseline cost was also reported
in previous studies [9, 31]. One further explanation for
higher baseline cost in patients turning out adherent or
participating in a PMP might be that they generally tend to
adhere to visit or examination schedules more stringently.
Furthermore they more often consult physicians and other
healthcare providers for a second opinion.
Our study is subject to several limitations. First,
randomization of the intervention (i.e., participation in the
PMP) was not performed due to the observational nature
of the study. Therefore, participation in the PMP may have
been biased by self-selection of patients. PMP participants
are generally more likely to take an active role in managing
their own care and may already have been more motivated
beforehand. Second, the participating group included those
patients who participated only for part of the study dur-
ation. Therefore, the effects of the PMP suggested by the
results of this study may underestimate the true magnitude
of the impact of such programs. Third, regarding the eco-
nomical outcome of the study the administrative cost of
the care management program and the cost for the drug
IM IFNb-1a itself has not been taken into account. Lastly,
the effect of disease management may take years to be-
come evident in patients’ health outcome and in the
utilization of healthcare services [36]. Therefore this study,
based on the relatively short follow-up period of one year,
may miss long-term beneficial or detrimental effects or
cost. Regarding the clinical outcomes, the observed reduc-
tions in relapse rates during treatment may have been
affected by the regression to the mean phenomenon. Due
to all these limitations, the results of the C.A.R.E. study
should be regarded as preliminary and should be inter-
preted with due caution. Clearly, further research on the
long-term effects of PMPs in MS patients is needed.
Conclusions
In conclusion, in this observational study involving MS
patients treated in with once weekly IM IFNb-1a routine
care settings, participation in the optional patient
management program MS-CARE was associated with
apparently better therapeutic and economical outcomes
in terms of improved medication adherence and lower
total MS-related cost over time. As was shown in other
therapeutic areas as well, structured patient manage-
ment programs for MS patients may play a beneficial
role in managing patient´s expectations and mitigating
side-effects. PMPs may exert appreciable effects on
treatment adherence and overall quality of care.
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